Home > Healthcare & Medical Devices > Digital Therapeutics Market

Digital Therapeutics Market Size By Component (Software, Device) By Application (Diabetes, Obesity, Cardiovascular, Mental & Behavioral Health, Hypertension, Insomnia) By Sales Channel (Business-to-business (B2B), Business-to-consumers (B2C)), Industry Analysis Report, Application Potential, Competitive Market Share & Forecast, 2023-2032

  • Report ID: GMI5408
  • Published Date: Dec 2022
  • Report Format: PDF

Industry Overview

Digital Therapeutics Market size exceeded a valuation of USD 6.5 billion in 2022 and is estimated to expand at 31.5% CAGR from 2023 to 2032. A remarkable surge in incidences of chronic diseases globally is seen as a prominent factor driving the demand for digital therapeutics.
 

Get more details on this report - Request Free Sample PDF
 

Non-communicable diseases such as diabetes, obesity, and CVDs have become increasingly prominent over recent years owing to the growing adoption of an unhealthy or sedentary lifestyle, changing dietary preferences, and an increased intake of tobacco and alcohol. Based on recent WHO statistics, an estimated 13% of adults across the globe are obese.
 

Rising security concerns to act as a progress barrier

Rising concerns pertaining to a lack of data security and privacy across developing and underdeveloped economies may emerge as a growth restraining factor over the ensuing years. The absence of fail-safe data security while executing digital therapeutics solutions may put the hospitals' and physicians' businesses at stake and incur vast losses of confidential and critical information. This may adversely affect the results of operations and reputation and thus may impact the overall market dynamics.
 

Growing prominence of chronic health disorders to push the segment expansion

Get more details on this report - Request Free Sample PDF
 

In terms of components, the digital therapeutics market is bifurcated into software and device. The software segment amassed over 90% business share in 2022 and is expected to be worth over USD 95.5 billion by 2032. Digital software solutions are critical to ensuring adherence to dose recommendations in patients suffering from chronic ailments such as chronic obstructive pulmonary disease, diabetes, etc. Besides, these solutions help induce long-term behavioral changes in patients through personalized care, which may further boost their adoption.
 

Increasing technological advancements to propel product adoption among diabetic patients

Regarding the application landscape, the diabetes segment is poised to amass more than USD 27.5 billion by 2032. This is credited to the growing prevalence of diabetes and the emergence of several technologically advanced diabetes management apps introducing tasks and fitness programs focused on training people in self-management of the disease. Nonetheless, the increased cognition of the benefits of digital therapeutics in the precise management of diabetes will propel segment revenues.
 

B2B sales channel to flourish due to streamlined supply chain

Get more details on this report - Request Free Sample PDF
 

Digital therapeutics market from B2B segment accumulated approximately 69% business share in 2022 and is anticipated to depict a moderate CAGR through 2032. Business-to-business sales channels offer a number of advantages when it comes to the distribution of digital therapeutic products. This may include exchanging products and services among businesses, extending their geographical reach, offering easy access to customers, and reducing stockholding & distribution costs, among others. Thus, the benefits associated with the concerned sales channel will help the digital therapeutics industry flourish.
 

Supportive government initiatives to boost industry size across the Asia Pacific

Get more details on this report - Request Free Sample PDF
 

Asia Pacific digital therapeutics market was valued at over USD 825 million in 2022 and is slated to showcase above 34.5% CAGR from 2023 to 2032. The regional expansion can be attributed to the growing consumer awareness about digital therapeutics and an increasing number of local startups foraying into advanced DTx solutions. In addition, governments across several regional economies have been undertaking initiatives and have been emphasizing the adoption of digital health solutions.
 

New product development remains the key growth strategy

Leading companies operating in the digital therapeutics industry include Omada Health, Virta Health Corp., Biofourmis, Inc., Akili Interactive Labs, Lark Health, Pear Therapeutics, Inc., Propeller Health (ResMed), Teladoc Health, LifeScan, Inc., DarioHealth, Voluntis, My Sugr (Roche), Welldoc, Otsuka Holdings, Co., and Click Therapeutics, Inc. Enterprises in the industrial vertical have been focusing on leveraging advanced technologies and introducing products with improved functionalities to sustain the market competition.
 

Impact of COVID-19 on the digital therapeutics market trends

The COVID-19 pandemic rendered a significantly positive impact on the digital therapeutics industry. The stringent regulatory measures imposed during the initial months of the crisis to curb the transmission of SARS-CoV-2 limited patient footfalls across hospitals and medical clinics. Besides, a majority of conditions were placed under the non-emergent category, resulting in delays and cancellation of patient appointments. These factors, in tandem, induced increased pressure on healthcare authorities and escalated the adoption of digital therapeutic solutions in-home care settings to meet the personalized requirements of patients without visiting hospitals.
 

The digital therapeutics market report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2018 to 2032 for the following segments:

By Component

  • Software
  • Device

By Application

  • Diabetes
  • Obesity
  • Cardiovascular
  • Mental & Behavioral Health
  • Hypertension
  • Insomnia
  • Others

By End-use

  • B2B
  • B2C

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Singapore
  • Latin America
    • Brazil
    • Mexico 
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • Israel

 

Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

Global market for digital therapeutics was worth over USD 6.5 billion in 2022 and is predicted to depict 31.5% CAGR from 2023 to 2032 owing to a noticeable rise in the prevalence of chronic health disorders.
Software segment is primed to drive a valuation worth over USD 95.5 billion by 2032 attributed to the increased utilization of digital software solutions in inducing long-term behavioral changes ensuring adherence to dose recommendations in patients undergoing treatment for chronic diseases.
Digital therapeutics market from the diabetes segment is anticipated to garner more than USD 27.5 billion by 2032 on account of the widely expanding diabetic patient pool and the increased awareness about the advantages of digital therapeutics in the precise control and management of diabetes.
Asia Pacific digital therapeutics industry is primed to showcase above 34.5% CAGR from 2023 to 2032 due to a supportive regulatory framework and increasing consumer awareness about these therapeutics.

Buy Now

Immediate Delivery Available

Premium Report Details

  • Base Year: 2022
  • Companies covered: 15
  • Tables & Figures: 192
  • Countries covered: 17
  • Pages: 169
  • Upcoming Report: Details can be customized to meet your information and data needs. Feel free to share your detailed research requirements via this form.

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount